Astria Therapeutics Inc [NASDAQ: ATXS] stock went on an upward path that rose over 3.89% on Wednesday, amounting to a one-week price increase of more than 6.08%.
Over the last 12 months, ATXS stock rose by 46.42%. The one-year Astria Therapeutics Inc stock forecast points to a potential upside of 45.07. The average equity rating for ATXS stock is currently 2.75, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $747.24 million, with 56.43 million shares outstanding and 49.96 million shares in the current float. Compared to the average trading volume of 1.79M shares, ATXS stock reached a trading volume of 5732337 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Astria Therapeutics Inc [ATXS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATXS shares is $23.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATXS stock is a recommendation set at 2.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Astria Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 12, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $16 to $20. The new note on the price target was released on September 17, 2025, representing the official price target for Astria Therapeutics Inc stock. Previously, the target price had yet another raise to $47, while Cantor Fitzgerald analysts kept a Overweight rating on ATXS stock.
The Price to Book ratio for the last quarter was 5.36, with the Price to Cash per share for the same quarter was set at 3.99.
ATXS Stock Performance Analysis:
Astria Therapeutics Inc [ATXS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.08. With this latest performance, ATXS shares gained by 5.65% in over the last four-week period, additionally plugging by 147.92% over the last 6 months – not to mention a rise of 46.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATXS stock in for the last two-week period is set at 73.76, with the RSI for the last a single of trading hit 0.24, and the three-weeks RSI is set at 0.29 for Astria Therapeutics Inc [ATXS]. The present Moving Average for the last 50 days of trading for this stock 11.10, while it was recorded at 12.71 for the last single week of trading, and 7.18 for the last 200 days.
Insight into Astria Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Astria Therapeutics Inc [ATXS] shares currently have an operating margin of -19335.69% and a Gross Margin at 0.00%. Astria Therapeutics Inc’s Net Margin is presently recorded at -17567.99%.
Astria Therapeutics Inc (ATXS) Capital Structure & Debt Analysis
According to recent financial data for Astria Therapeutics Inc. ( ATXS), the Return on Equity (ROE) stands at -43.15%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -39.16%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Astria Therapeutics Inc’s Return on Invested Capital (ROIC) is -52.49%, showcasing its effectiveness in deploying capital for earnings.
Astria Therapeutics Inc (ATXS) Efficiency & Liquidity Metrics
Based on Astria Therapeutics Inc’s (ATXS) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Astria Therapeutics Inc (ATXS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Astria Therapeutics Inc. (ATXS) effectively leverages its workforce, generating an average of -$1590128.21 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.78% and a Quick Ratio of 10.78%, indicating strong ability to cover short-term liabilities.
ATXS Stock EPS
With the latest financial reports released by the company, Astria Therapeutics Inc posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.45/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATXS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Astria Therapeutics Inc go to -2.36%.
Astria Therapeutics Inc [ATXS] Institutonal Ownership Details
There are presently around $89.14%, or 89.57%% of ATXS stock, in the hands of institutional investors. The top three institutional holders of ATXS stocks are: PERCEPTIVE ADVISORS LLC with ownership of 6.49 million shares, which is approximately 11.4815%. FMR LLC, holding 6.05 million shares of the stock with an approximate value of $$55.1 million in ATXS stocks shares; and FMR LLC, currently with $$45.9 million in ATXS stock with ownership which is approximately 8.9292%.
